focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And by the way, since you are the one who used it as an argument, why are you now asking someone else to explain it?
Because you are full of poo poo :)
Lmao. OK. Got it now. Good luck with that attitude.
As I have signed many CDAs over the years I can tell you that this is not the case. What the other party might want is avoiding disclosure that they are interested, they cannot prevent scancell from communicating their own data. That only happens if they have pre agreed terms, nothing to do with CDA/NDA. And it's too early according to company.
Again, since you are sooooo good at getting replies, why don't you ask them this:
Scope open label study passed onto stage 2 with the data that were presented in September 2023. Two months later you provided an update on scope, shortly before the capital raise. Why haven't you updated investors since?
I block fools who are trying to manipulate share prices and obtain inside info to use to trade against other shareholders…..so, having reviewed their posting history, there’s another one blocked…..🙄
Bermuda,
ee - why/how would issuing positive clinical trial updates prejudice commercial discussions?
If I were involved I’d be seeking to negotiate with multiple parties under an NDA. Nobody likes negotiating with a party that they think is unjustifiably seeking to pump up its share price by dropping hints.
Different, of course, when the Q3 trial endpoints are reached - but I’d expect a deal to be ready-to-go at that point and to make one big announcement.
"prejudicing commercial discussions".
This is hilarious. How *exactly* updating on an open label study is "prejudicing commercial discussions"? The only time this happens is when thry already have a good deal that is conditional upon future data and the partner (buyer) has insisted that they don't publicly disclose until final, at which point the deal moves forward as pre agreed.
Except scancell already said it is too early for a deal and that should happen as we approach the phase 3 part of the next phase2/3 trial.
You use nonsense about food or fishing or whatever that I've seen so many times in these forums. That's how one gets hurt. Get real.
Scinv_Temp, BOJO - You're not the first to have issues with replies to emails. Not sure how you sent your mail, but they seem to have a particular problem with the 'contact us' link on their website and it may simply be a question of nobody picking up your messages rather than a deliberate decision to ignore them. It's something they need to address (along with a couple of other issues with their website).
ee - why/how would issuing positive clinical trial updates prejudice commercial discussions?
Try sending them to a real person, rather than
makemeloadsofmoneyquickly@scancell.dosh
…..
EE,
Well I don't get replies to my emails from Scancell (I have tried several times). I have no problems in communications with other companies I am invested in. They should respond to all emails.
Has it occurred to you that the reason they raised money in December was because a) they needed to disclose an update prior to raise and b) they knew perfectly well that they wouldn’t be able to make such a disclosure this spring without prejudicing commercial discussions?
I guess not 🙄
That is clearly why they raised earlier than many expected - and why they are now busy popping up at every conference, spreading pre-deal groundbait on the water……
I have no trouble getting emails replied to. But then I don’t use them to excess and neither do I ask them questions that I know perfectly well they aren’t at liberty to disclose except via RNS (eg questions about unpublished trial results).
There is no event-driven company on the planet that gives a running commentary between news events.
Final, I promise Because I'm allergic to BS. This is what the CEO said in the placing RNS (before the actual placing):
"Commenting on the proposed Capital Raise, Prof Lindy Durrant, Chief Executive Officer, said: “Scancell is producing highly-significant data across its pipeline of cancer vaccines. The recent updates from the SCOPE study are showing previously unseen response rates in melanoma including an objective response rate of over 85 per cent. and a complete responder. The study remains on track with data expected in H1 2024 and based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful."
H1 2024, so that "Q3" is not very consistent guidance, is it?
In fact it is quite recent.
(OK I'm done)
One last thing. I went back and checked the RNSs. September 2023, they reported on 11 patients and that they succesfully completed stage 1 of the trial (since then we are in Simon's stage 2). 2 months afterwards, they reported on 13 patients while the trial had already progressed to stage 2, then then they did the placing and then they said no more updates. These are the facts. Again, have a nice day.
The final data, yes. I am talking about an update, like the did end of '23 just before they asked for money. The CEO basically said no more updates (after they got the money of course) until data is (almost) final. And you are supposed to be an investor who looks after their capital? I'll leave it here. Have a nice day.
Lindy has consistently stated that data should be available in Q3.
She says "should" because nothing is certain about the progress of clinical trials.
However, with Scancell putting in an appearance at every relevant conference, this is a clue to how the trials (especially the Scope trial) are going.
And a good investment can be tracked, but you need data for that, even if incomplete :) Maybe invest in a restaurant chain instead? Because this kind of attitude is how people lose their capital. How about sending them an email? I have, and they have not replied. Can you do it better?
A good meal is worth waiting for 😎
Well, you got nothing so far 🤷♀️
Strange that you would be happy with a regular supply of bones.
I’d prefer a three-course meal.🤷♂️
Yet they didn't mind updating us end of 2023 with incomplete data when they had already presented incomplete data in September or October 2023, because they needed money. Once they got it, they decided to poop on the people who provided and just talk to everyone else. A small company I know, but it is not too complex to throw investors a bone, is it?
Sorry that should be 2024.
Oops
The company cannot conjure up results from partial incomplete data. It is also unfortunate that both of our trials have conspired to reach important data points around the same time. Third / fourth quarter 2025.
That’s just down to enrolment, selection, planned dosing, medical scans and data analysis. Even then they cannot report on individual cases so enough data has to be verified before it can be compiled and released in an RNS.
By reading the various RNS’s about how the trails are progressing it is sensible not to expect the trial reports until we are beyond the first half of 2024.
However, there is always the possibility that the company could announce news on a deal at any time.
Waiting is frustrating but it will be worth it if the data continues on the positive upward trajectory as previously reported.
When are they gonna present some results to shareholders…
Https://www.ejcancer.com/article/S0959-8049(24)00776-7/abstract
Not sure if these results could be directly compared to SCIB1. Perhaps, a good read for technical people.